| Characteristics | n (%) |
| Median age (years) | 11.2 |
| Sex: | |
| Female | 101 (69) |
| Male | 45 (31) |
| Onset JIA subtype: | |
| Systemic | 39 (27) |
| Polyarticular rheumatoid factor positive | 11 (8) |
| Polyarticular rheumatoid factor negative | 55 (38) |
| Oligoarticular extended | 28 (19) |
| Enthesitis related arthritis | 5 (3) |
| Juvenile arthritis psoriatica | 8 (5) |
| Unclassified | 0 (0) |
| Median JIA disease duration (years) | 4.1 |
| History of drug use before start of etanercept: | |
| NSAIDs | 141 (97) |
| Glucocorticoids systemic | 90 (62) |
| Glucocorticoids intra-articular | 60 (41) |
| MTX | 146 (100) |
| Other DMARDS | 74 (51) |
| Use of other concomitant drugs at start of etanercept: | |
| NSAIDs | 122 (84) |
| Glucocorticoids | 67 (46) |
| MTX | 113 (77) |
| Other DMARDS | 13 (9) |
DMARD, disease-modifying antirheumatic drug; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.